Introductory Chapter: Pertussis - Disease, Control and Challenges

Dias, Waldely de Oliveira

doi:10.5772/intechopen.77134

Cited by 1 publication

(2 citation statements)

References 22 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(1) At least 87.5% of mice immunized with each dilution of the standard and experimental vaccines should survive after the 14-day immunization period [22]. (2) The trial is validated if the titration of the B. pertussis suspension indicates that the test dose of 0.03 mL will contain 100 and 1000 LD50, and the number of colony-forming units CFU in 1 LD50 must not be more than 300 colonies and the number of CFU in the last dose of challenge suspension must not be less than 10. (3) The assay is validated if the ED50 of each vaccine was between the lowest and highest dose used to immunize the mice, and if the probit regression of the proportion of mice protected as a function of the logarithm of the dose of each vaccine preparation was significant (p ≤ 0.05).…”

Section: Validity Criteriamentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the Potency of the Pertussis Vaccine in Experimental Infection Model with Bordetella pertussis: Study of the Case of the Pertussis Vaccine Used in the Expanded Vaccination Program in Algeria

et al. 2022

View full text Add to dashboard Cite

In Algeria, vaccination against pertussis is carried out using the whole-cell pertussis vaccine combined with the diphtheria and tetanus toxoids (DTwp). The quality control of vaccines locally produced or imported is carried out before the batch release. The aim of our work was to evaluate the potency of pertussis vaccines. In the present study, five consecutive trials of potency were conducted on samples of the same batch of (DTwp) using the mouse protection test (MPT) against experimental infection of Bordetella pertussis strain 18323, based on the Kendrick test. The virulence of B. pertussis strain 18–323 was verified by the mortality of mice, with an average LD50 of 338.92, as well as the dose of the lethal test containing a mean number of LD50 of 324.43. The (MPT) test recorded a relative potency of 8.02 IU/human dose, with 95% CL of (3.56–18.05) IU/human dose. The development of the (MPT) at the laboratory of quality control of vaccines and sera at the Pasteur Institute of Algeria was effective in evaluating the potency of whole-cell pertussis vaccines. Interestingly, our study indicates that this potency is necessary for the vaccine quality assurance. Further validation is needed to strengthen the application and routine use of the test.

show abstract

Section: Validity Criteriamentioning

confidence: 99%

“…Pertussis is a strictly human respiratory tract disease and is highly contagious, caused by the bacterium Bordetella pertussis, which is characterized by the secretion of several adhesins and toxins [1][2][3]. In recent years, the resurgence of Pertussis remains a public health problem [4][5][6].…”

Section: Introductionmentioning

confidence: 99%